search

All clinical trials

Results 460181-460190 of 470744

Treatment Use of Generex Oral-lyn™ in Patients With Diabetes

Type 1 Diabetes MellitusType 2 Diabetes Mellitus

The objective of this Treatment IND protocol is to provide Generex Oral-lyn™ to patients with serious or life-threatening Type 1 or Type 2 diabetes mellitus, with no satisfactory alternative therapy available for treatment of diabetes, and who are not eligible to participate in the ongoing pivotal clinical trial (Protocol GEN-084-OL). This protocol is intended as a substitute for the Single Patient IND mechanism to obtain Generex Oral-lyn™.

No longer available1 enrollment criteria

Talent Aortic Cuff Stent Graft System Compassionate Use Registry

Abdominal Aortic Aneurysms

An evaluation of the TALENT Aortic Cuff in patients with existing AneuRx stent grafts who have experienced sub-optimal stent graft outcomes and are not deemed suitable candidates for treatment with an AneuRx Aortic Cuff.

No longer available16 enrollment criteria

Erwinase Master Treatment Protocol

LeukemiaAcute Lymphoblastic1 more

The purpose of this study is to make Erwinase available to patients with acute lymphoblastic leukemia (ALL) who have had previous allergic reactions to certain formulations of L-asparaginase.

No longer available6 enrollment criteria

Emergency/Compassionate Use PFO Occluder

Patent Foramen OvalePFO

Emergency/compassionate use for the AMPLATZER PFO Occluder

Approved for marketing1 enrollment criteria

Stone Disease in Children and Their Families

HypercalciuriaUrolithiasis

The hypothesis of this study proposal is that pediatric urinary stone formers have genetic risk factors which predispose their urinary stone production. 50-60% of pediatric stone patients have a positive family history of urinary stone disease. Several genetic mutations have been identified which predispose patients to various types of urinary stones. These genetic mutations can also lead to other significant sequela besides stones, including osteopenia/osteoporosis (bone loss). Furthermore, metabolic abnormalities can be identified in more than 50% of pediatric stone formers, some of which can be improved and/or alleviated with medical intervention to help decrease rate of stone formation and the need for hospitalization and surgical intervention.

Available2 enrollment criteria

A Phase III Second Line Trial in Advanced Pancreatic Cancer CONKO 003

Pancreatic Cancer

The purpose of this study is to compare best supportive care plus oxaliplatin/ folinic acid/ 5-FU versus best supportive alone in patients with gemcitabine refractory pancreatic cancer.

Approved for marketing8 enrollment criteria

The Paroxysmal Nocturnal Hemoglobinuria Early Access Treatment Protocol

HemoglobinuriaParoxysmal

The primary objective is to provide access to eculizumab for PNH patient pending commercial availability.

Approved for marketing8 enrollment criteria

Treatment of Patients With Age-Related Macular Degeneration With Anecortave Acetate

Macular Degeneration

The purpose of this study is to evaluate whether anecortave acetate can slow or stop the progression of age-related macular degeneration in patients who do not qualify for other studies and have no other treatment options.

No longer available6 enrollment criteria

Treatment Use Study With Sunitinib (SU011248) For Patients With Cytokine-Refractory Metastatic Renal...

CarcinomaRenal Cell

The primary objective of this protocol is to provide access to SU011248 treatment for patients with metastatic RCC who are ineligible for participation in ongoing SU011248 clinical studies and have the potential to derive clinical benefit from treatment with SU011248 based on the judgment of the investigator.

Approved for marketing2 enrollment criteria

Expanded Access to Immunomodulatory AVM0703 for Solid Tumor and Blood Cancer Patients

GlioblastomaSquamous Cell Carcinoma14 more

AVM Biotechnology, Inc., provides immunomodulatory AVM0703 to solid tumor and blood cancer patients upon request by a US licensed MD or DO. As of July 2023, 22 patients have been treated through this FDA-EAP including patients diagnosed with relapsed or recurring glioblastoma, inoperable/chemotherapy ineligible CNS Squamous Cell Carcinoma, metastatic Breast Cancer, ovarian cancer, gastric cancer, Hodgkin's Lymphoma, Mixed Phenotype Acute Myelogenous Leukemia, colon cancer, B-ALL, Malignant Myxoid Spindle Cell Neoplasm, non-small cell lung cancer, DLBCL with CNS involvement, metastatic prostate cancer, Anaplastic T-cell Non-Hodgkin's Lymphoma.

Available2 enrollment criteria
1...460184601946020...47075

Need Help? Contact our team!


We'll reach out to this number within 24 hrs